About Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / Sales0.32
Price / CashN/A
Book Value$1.49 per share
Price / Book0.00
Return on EquityN/A
Return on AssetsN/A
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Frequently Asked Questions
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."
How were Epirus Biopharmaceuticals' earnings last quarter?
Epirus Biopharmaceuticals Inc (OTCMKTS:EPRSQ) released its earnings results on Tuesday, March, 15th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. View Epirus Biopharmaceuticals' Earnings History.
Who are some of Epirus Biopharmaceuticals' key competitors?
Some companies that are related to Epirus Biopharmaceuticals include Glori Energy (GLRI), Prospect Global Resources (PGRX), QF Liquidation (QTWWQ), M Pharmaceutical (MPHMF), Azure Midstream Pa Com Unit Ltd Partner Int (AZURQ), Roust (CEDCQ), James River Coal (JRCCQ), Violin Memory (VMEMQ), Noranda Aluminum (NORNQ), DS Healthcare Group (DSKX), Erickson (EACIQ), Trimedyne (TMED), Ignite Restaurant Group (IRGTQ), Imris (IMRSQ), First NBC Bank (FNBC), Miller Energy Resources (MILLQ), Coldwater Creek (CWTRQ) and Xtera Communications (XCOMQ).
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Robert Ticktin, Senior Vice President, General Counsel, Secretary (Age 53)
- Vincent E. Aurentz, Chief Business Officer
How do I buy Epirus Biopharmaceuticals stock?
Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epirus Biopharmaceuticals' stock price today?
One share of Epirus Biopharmaceuticals stock can currently be purchased for approximately $0.01.
How big of a company is Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals has a market capitalization of $180,000.00 and generates $580,000.00 in revenue each year.
How can I contact Epirus Biopharmaceuticals?
Epirus Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The biopharmaceutical company can be reached via phone at 617-600-3497 or via email at [email protected]
MarketBeat Community Rating for Epirus Biopharmaceuticals (EPRSQ)MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings History and Estimates Chart
Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2014||Q114||$0.20||($0.15)||$9.00 million||$1.60 million||View||N/A|
|8/1/2013||Q2 2013||($0.07)||($0.08)||$2.91 million||$3.89 million||View||N/A|
|5/2/2013||Q1 2013||($0.07)||($0.06)||$3.44 million||$3.70 million||View||N/A|
|3/6/2013||Q4 2012||($0.08)||($0.06)||$3.12 million||$3.67 million||View||N/A|
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Epirus Biopharmaceuticals (OTCMKTS:EPRSQ)
No dividend announcements for this company have been tracked by MarketBeat.com
Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.06%
Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/21/2015||Robert Ticktin||General Counsel||Buy||3,000||$3.72||$11,160.00|| |
|12/17/2015||Aurentz Vincent||Insider||Buy||2,200||$3.43||$7,546.00|| |
|12/16/2015||Amit Munshi||CEO||Buy||8,270||$2.80||$23,156.00|| |
|12/15/2015||Amit Munshi||CEO||Buy||8,069||$2.87||$23,158.03|| |
|12/9/2015||Amit Munshi||CEO||Buy||13,190||$4.07||$53,683.30|| |
|12/9/2015||Aurentz Vincent||Insider||Buy||2,800||$3.85||$10,780.00|| |
|9/21/2015||Amit Munshi||CEO||Buy||10,000||$6.19||$61,900.00|| |
|9/18/2015||Amit Munshi||CEO||Buy||10,000||$5.99||$59,900.00|| |
|2/6/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||167,316||$5.00||$836,580.00|| |
|2/4/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||52,684||$4.98||$262,366.32|| |
|2/4/2015||Scott M Rocklage||Director||Buy||400,000||$5.00||$2,000,000.00|| |
|1/26/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||38,516||$6.47||$249,198.52|| |
|1/23/2015||Montreux Equity Partners Iv Lp||Major Shareholder||Sell||22,530||$6.29||$141,713.70|| |
Epirus Biopharmaceuticals (OTCMKTS EPRSQ) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) SEC Filings
Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) Income Statement, Balance Sheet and Cash Flow Statement
Epirus Biopharmaceuticals (OTCMKTS EPRSQ) Stock Chart for Monday, December, 11, 2017